The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The effect of hepatic insufficiency on the pharmacokinetics of ridaforolimus.
J. B. McCrea
Employment or Leadership Position - Merck
Stock Ownership - Merck
Research Funding - Merck
M. Stroh
Employment or Leadership Position - Merck
Stock Ownership - Merck
X. Li
Employment or Leadership Position - Merck
Stock Ownership - Merck
V. Schulz
Employment or Leadership Position - Merck
Stock Ownership - Merck
J. Talaty
Employment or Leadership Position - Merck
Stock Ownership - Merck
K. W. Orford
Stock Ownership - Merck
Research Funding - Merck
Other Remuneration - Merck
M. Trucksis
Employment or Leadership Position - Merck
Stock Ownership - Merck
Research Funding - Merck
K. Lasseter
No relevant relationships to disclose
N. Agrawal
Employment or Leadership Position - Merck
Stock Ownership - Merck; Merck (I)
J. A. Wagner
Employment or Leadership Position - Merck
Stock Ownership - Merck
M. Iwamoto
Employment or Leadership Position - Merck
Stock Ownership - Merck